Tesamorelin vs Sermorelin vs Ipamorelin: A Receptor-Level Comparison

Sermorelin is GRF(1-29)-NH₂: the first 29 residues of natural growth-hormone-releasing hormone, amidated, with no further modification. Classic structure–activity work established that these 29 residues carry the hormone's full receptor activity, which made the fragment the canonical minimal scaffold of the GHRH family (Frohman LA, Jansson JO. Endocr Rev. 1986;7(3):223–253). Its laboratory weakness is equally canonical: as an unmodified natural sequence it is degraded rapidly, with dipeptidyl peptidase-4 clipping the N-terminus within minutes in plasma-containing systems. In modern comparison work, that combination — full activity, no engineering — is exactly what makes sermorelin useful: it is the natural-sequence reference against which engineered analogues are measured.

Tesamorelin takes the opposite approach on both axes: it is the complete 44-residue GHRH sequence rather than the 1-29 fragment, and it carries a deliberate chemical modification — a trans-3-hexenoic acid group capping the N-terminus. That cap sits directly on the site DPP-4 attacks, and the published preclinical characterization shows the modification confers substantial resistance to that degradation route while preserving GHRH-receptor agonism (Ferdinandi ES, et al. Basic Clin Pharmacol Toxicol. 2007;100(1):49–58). Same receptor as sermorelin, same Gs/cAMP signaling program — the differences are the full-length backbone and the engineered N-terminus. In a chromatogram or mass spectrum the two are unmistakably different molecules (~5,136 vs ~3,358 Da), a point that matters when verifying which GHRH analogue a vial actually contains. The full single-compound treatment is at Tesamorelin.

Ipamorelin does not belong to the GHRH family at all. It is a five-residue synthetic peptide (Aib-His-D-2-Nal-D-Phe-Lys-NH₂) from the growth-hormone-secretagogue medicinal-chemistry series, and its receptor is GHS-R1a — the ghrelin receptor, a class A GPCR signaling through Gq and intracellular calcium rather than the GHRH receptor's Gs/cAMP program (Howard AD, et al. Science. 1996;273(5277):974–977). The original characterization work made its reputation on receptor selectivity within its own class (Raun K, et al. Eur J Endocrinol. 1998;139(5):552–561). Comparing ipamorelin to tesamorelin or sermorelin is therefore not comparing two versions of one mechanism — it is comparing two arms of an axis: different receptor family, different second messenger, different upstream circuitry. The full treatment is at Ipamorelin.

Tesamorelin vs sermorelin is an engineering comparison. Same receptor, same signaling readout — the experimental difference is stability and backbone length. A design comparing the two in a plasma-containing system is largely measuring the value of the N-terminal cap; in a clean buffer system with short incubations, their receptor pharmacology converges. Sermorelin's role as the unmodified reference is what makes that comparison interpretable.

Anything vs ipamorelin is a receptor comparison. Readouts must be chosen for the receptor: cAMP accumulation reports the GHRH arm; calcium flux reports the ghrelin arm. Running a cAMP-only assay across all three compounds structurally understates the ipamorelin arm — the same readout-selection principle covered in the incretin receptor comparison, applied to a different axis.

The two arms are also combined rather than compared. Because the GHRH and ghrelin receptors sit on the same target cells with complementary signaling, the pairing logic runs the other way in blend form — covered in the CJC-1295 + Ipamorelin overview.

Identity verification is the precondition for any of it. Three compounds spanning ~712 to ~5,136 Da with distinct modification signatures are trivially distinguishable by mass spectrometry — when testing is performed. Certificates of Analysis are published on product pages as testing is completed — review the report before you order.